190 related articles for article (PubMed ID: 160589)
21. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.
Ofosu FA; Blajchman MA; Modi GJ; Smith LM; Buchanan MR; Hirsh J
Br J Haematol; 1985 Aug; 60(4):695-704. PubMed ID: 2411283
[TBL] [Abstract][Full Text] [Related]
22. Placental protein 5 is related to blood coagulation and fibrinolytic systems.
Siiteri JE; Koistinen R; Salem HT; Bohn H; Seppälä M
Life Sci; 1982 May; 30(22):1885-91. PubMed ID: 6213827
[TBL] [Abstract][Full Text] [Related]
23. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.
Fischer AM; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1982 Apr; 47(2):104-8. PubMed ID: 6179182
[TBL] [Abstract][Full Text] [Related]
24. Antithrombin III: a backward glance o'er travel'd roads.
Seegers WH
Adv Exp Med Biol; 1975; 52():195-215. PubMed ID: 47704
[TBL] [Abstract][Full Text] [Related]
25. Role of heparin in the interaction of serine proteinases with antithrombin III.
Stürzebecher J
Acta Biol Med Ger; 1977; 36(11-12):1893-7. PubMed ID: 151469
[TBL] [Abstract][Full Text] [Related]
26. Heparin neutralization of PGI2: effects upon platelets.
Saba HI; Saba SR; Blackburn CA; Hartmann RC; Mason RG
Science; 1979 Aug; 205(4405):499-501. PubMed ID: 377493
[TBL] [Abstract][Full Text] [Related]
27. Heparin and protease inhibition. I. Heparin complexes with thrombin, plasmin, and trypsin.
Smith GF; Sundboom JL
Thromb Res; 1981 Apr 1-15; 22(1-2):103-14. PubMed ID: 6457413
[No Abstract] [Full Text] [Related]
28. Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation.
Pieters J; Willems G; Hemker HC; Lindhout T
J Biol Chem; 1988 Oct; 263(30):15313-8. PubMed ID: 3262615
[TBL] [Abstract][Full Text] [Related]
29. Actions and interactions of antithrombin and heparin.
Rosenberg RD
N Engl J Med; 1975 Jan; 292(3):146-51. PubMed ID: 127943
[No Abstract] [Full Text] [Related]
30. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
[TBL] [Abstract][Full Text] [Related]
31. Anticoagulating and non-enzymatic fibrinolytic activities of heparin-antithrombin III and antithrombin III-heparin-thrombin complexes in vitro and in vivo.
Kudrjashov BA; Pastorova VE; Lyapina LA
Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(5):731-42. PubMed ID: 6198257
[TBL] [Abstract][Full Text] [Related]
32. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin.
Buchanan MR; Boneu B; Ofosu F; Hirsh J
Blood; 1985 Jan; 65(1):198-201. PubMed ID: 3965047
[TBL] [Abstract][Full Text] [Related]
33. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin.
Holmer E; Kurachi K; Söderström G
Biochem J; 1981 Feb; 193(2):395-400. PubMed ID: 6914196
[TBL] [Abstract][Full Text] [Related]
34. Changes of prekallikrein in the cases with disseminated intravascular coagulation syndrome.
Sakuragawa N; Takahashi K; Shibata A
Adv Exp Med Biol; 1979; 120B():185-93. PubMed ID: 160191
[TBL] [Abstract][Full Text] [Related]
35. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.
Lane DA; Denton J; Flynn AM; Thunberg L; Lindahl U
Biochem J; 1984 Mar; 218(3):725-32. PubMed ID: 6721831
[TBL] [Abstract][Full Text] [Related]
36. The anticoagulant properties of mast cell product, chondroitin sulphate E.
Scully MF; Ellis V; Seno N; Kakkar VV
Biochem Biophys Res Commun; 1986 May; 137(1):15-22. PubMed ID: 3087353
[TBL] [Abstract][Full Text] [Related]
37. Molecular weight of heparin versus biologic activity. Some additional considerations.
Losito R; Losito C
Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
[No Abstract] [Full Text] [Related]
38. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
Elgue G; Blombäck M; Olsson P; Riesenfeld J
Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
[TBL] [Abstract][Full Text] [Related]
39. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma.
Ofosu FA; Modi G; Cerskus AL; Hirsh J; Blajchman MA
Thromb Res; 1982 Nov; 28(4):487-97. PubMed ID: 7164033
[TBL] [Abstract][Full Text] [Related]
40. The role of the COOH-terminal region of antithrombin III. Evidence that the COOH-terminal region of the inhibitor enhances the reactivity of thrombin and factor Xa with the inhibitor.
Nishioka J; Suzuki K
J Biol Chem; 1992 Nov; 267(31):22224-9. PubMed ID: 1331047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
